| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T278 |
0-4 |
Sentence |
denotes |
3.5. |
| T279 |
5-26 |
Sentence |
denotes |
Maraviroc (Selzentry) |
| T280 |
27-312 |
Sentence |
denotes |
It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. |
| T281 |
313-346 |
Sentence |
denotes |
The drug was approved by the U.S. |
| T282 |
347-390 |
Sentence |
denotes |
FDA in 2007 as an oral treatment for HIV-1. |
| T283 |
391-521 |
Sentence |
denotes |
The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. |
| T284 |
522-607 |
Sentence |
denotes |
Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. |
| T285 |
608-821 |
Sentence |
denotes |
However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]. |
